Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Endo International (GB:0Y5F)
LSE:0Y5F
Endo International (0Y5F) Share Price & Analysis
0 Followers
0Y5F Stock Chart & Stats
Day’s Range$0.01 - $0.01
52-Week Range― - ―
Previous Close$0.01
Volume0.00
Average Volume (3M)N/A
Market Cap
$141.13K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 09, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
2.11%
Insiders
0.31% Mutual Funds
<0.01% Other Institutional Investors
97.58% Public Companies and
Individual Investors
0Y5F FAQ
What was Endo International’s price range in the past 12 months?
Currently, no data Available
What is Endo International’s market cap?
Currently, no data Available
When is Endo International’s upcoming earnings report date?
Endo International’s upcoming earnings report date is May 09, 2024 which is yesterday.
How were Endo International’s earnings last quarter?
Endo International released its earnings results on Mar 06, 2024. The company reported -$10.38 earnings per share for the quarter, missing the consensus estimate of N/A by -$10.38.
Is Endo International overvalued?
According to Wall Street analysts Endo International’s price is currently Overvalued.
Does Endo International pay dividends?
Endo International does not currently pay dividends.
What is Endo International’s EPS estimate?
Endo International’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Endo International have?
Currently, no data Available
What happened to Endo International’s price movement after its last earnings report?
Endo International reported an EPS of -$10.38 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Endo International?
Among the largest hedge funds holding Endo International’s share is Paulson & Co Inc. It holds Endo International’s shares valued at N/A.
---
Endo International Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.78%
Trailing 12-Months
Company Description
Endo International
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.
---
---